Icahn predicts 40% premium in Visx sell off
This article was originally published in Clinica
Executive Summary
Carl Icahn, a US financier who for some months has been aggressively attempting to take control of US laser eye surgery company Visx, has raised the stakes by claiming that he will be able to sell the company to an unnamed bidder for $32 a share if he gained control. That would represent a premium of more than 40% on the company's present share price of just over $19.